This has been confirmed by the results of two independent investigations which were presented in September 2009 at the congress of the Osteoarthritis Research Society International (OARSI) in Montreal.
A clinical trial performed by Harvard Medical School and Tufts Medical Center demonstrated the efficacy of Recogen® on the basis of magnetic resonance images (MRI). Working in collaboration with Kiel University, scientists at the Kiel-based Collagen Research Institute (CRI) then gathered experimental evidence of the effects of consumption of Recogen® on cartilage cells.
Using an objective imaging technique, the Tufts researchers, led by Dr Timothy McAlindon, found a significant regeneration of the cartilage tissue in the Recogen® group, compared to normal cartilage degeneration progression in the placebo group. The CRI’s cell experiments indicated that Recogen® induces the increased synthesis of aggrecan (an important component in cartilage) and Type II collagen (which plays a key role in cartilage elasticity).
The role of Recogen® in the treatment and prevention of osteoarthritis
The administration of Recogen® can prevent joint degeneration and counteract load-induced wear of the articular cartilage. Compared to other substances which focus on providing short-term pain relief, Recogen® tackles the root causes of osteoarthritis and cartilage degeneration. Previous clinical trials had already shown that the substance promotes mobility and reduces pain.
Classified as a safe nutritional product by the FDA, Recogen® is easy to synthesize. Furthermore, thanks to its neutral taste and odour, Recogen® can be easily added to the individual’s daily diet. Positive health effects can be achieved even with low doses. Recogen® is suitable for all age groups with particular benefit for athletes (competitive and amateur), elderly persons and all health-conscious individuals who want to prevent cartilage degeneration at an early stage.